Researchers have revealed the role of enzyme TYK2 in the aggregation of tau proteins, which contributes to Alzheimer’s ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today ann ...

Researchers found that inhibiting the enzyme TYK2 may reduce the harmful accumulation of tau protein in Alzheimer’s disease, ...

Scientists have discovered that the enzyme TYK2 modifies tau proteins, leading to their accumulation in the brain—a key ...

Baricitinib, an inhibitor of JAK1/2, was approved by both the FDA and European Medicines Agency in 2022 to treat moderate to ...

To this end, we are encouraged by the fact that others have developed TYK2 inhibitors that have been tested in humans for other indications. Studies are needed to see if these inhibitors indeed get ...

Researchers at Baylor College of Medicine, the Jan and Dan Duncan Neurological Research Institute (Duncan NRI) at Texas ...

Alumis Inc. (ALMS) has received a new Buy rating, initiated by Robert W. Baird analyst, Brian Skorney. Brian Skorney has given his Buy rating ...

TYK2 enzyme changes tau protein from a protective role to a harmful one, contributing to Alzheimer’s disease progression.

Topline results are anticipated in 2026. The Phase 1 clinical study of A-005, a potential first-in-class, central nervous system (CNS) penetrant TYK2 inhibitor being developed for the treatment of ...